The peptide Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) has been experimentally administered via subcutaneous, intramuscular, intranasal, and oral routes, whereas in many mechanistic studies, cells were directly exposed to the peptide in culture. However, the individual routes of administration have not been studied to the same extent, and robust data comparing human bioavailability or route-dependent safety are still lacking. [1–8]
The term „Epitalon by injection” can be misleading if it suggests that injection is the only or clinically established route of administration. In fact, the scientific literature covers many methods of administration chosen for very different experimental purposes. Subcutaneous injection dominates in older studies on lifespan and cancer, intranasal administration appears mainly in neurophysiological and pineal gland studies in rats, oral administration has been analysed in rodents, and some studies in non-human primates have used parenteral administration. There is little evidence to rank these routes in terms of efficacy or safety in humans.
Therefore, the route of administration used in the published experiment should be treated as part of a specific research protocol rather than as a general recommendation for use.
How was Epitalon administered in studies?
Epitalon has been administered subcutaneously in numerous ageing and cancer studies in rodents, intranasally in neurophysiological and pineal gland experiments in rats, orally in several gastrointestinal studies, and parenterally in studies on non-human primates. Direct exposure of cultured cells is also frequently used in mechanistic studies, but none of these routes constitutes a validated, universal route of administration in humans. [1–8]
Subcutaneous injection is the most commonly documented route in classical gerontological literature.
In a 2003 animal longevity study, Swiss-derived female SHR mice were administered Epitalon via subcutaneous injection for five consecutive days each month, starting from three months of age until natural death. [1]
In a related study on HER-2/neu transgenic mice, subcutaneous Epithalon was also used, administering 1 μg per mouse for five consecutive days each month. [2]
Other protocols in rodents used more frequent subcutaneous administration. Female rats kept under various lighting conditions received Epithalon five times a week from four months of age. [3]
The intranasal route was chosen for a different reason. In a 2007 study on the rat neocortex, researchers administered Epitalon intranasally and then recorded spontaneous activity of cortical neurones for 30 minutes. [4] Changes were observed within just a few minutes.
Oral administration was also investigated. In a 2002 study on old rats, Epithalon was administered per os for one month, and intestinal enzyme activity was evaluated. [5]
These studies show that Epitalon has been analysed using several routes of administration, but they do not prove their equivalence.
What is Epitalon injection?
In scientific literature, Epitalon injection means the administration of the defined AEDG preparation parenterally, most frequently subcutaneously in animal studies. This term describes the method of introducing the peptide into the experimental organism and does not imply the existence of an approved injectable product, a standard injection protocol for humans, or a confirmed clinical benefit.
In scientific terminology, parenteral administration means, broadly speaking, the delivery of a substance while bypassing the gastrointestinal tract.
In the case of Epitalon, the most common route of administration reported in the literature reviewed is subcutaneous injection.
An example is the longevity study of SHR mice, in which Epitalon was dissolved in saline and administered subcutaneously. [1] Another study on transgenic mice used the same general route while analysing the development of mammary tumours. [2]
Subcutaneous administration also appears in longevity and carcinogenesis studies in rats. In one experiment regarding colorectal carcinogenesis, male rats received Epitalon in repeated subcutaneous injections during various stages of chemically induced tumour development. [6]
The frequent use of injections was due to the convenience they offered for experimental purposes and the fact that they allowed for more controlled exposure than oral administration.
This does not mean that injectable Epitalon has been shown to be more effective, safer or more bioavailable in humans in comparative clinical trials.
The scientific literature also lacks a sufficiently well-characterised contemporary safety database regarding Epitalon injection in humans that would allow the determination of the frequency of adverse events, immunogenicity, injection site complications or the risks of repeated use.
What Does ‘Subcutaneous Administration’ Mean?
Subcutaneous administration means placing a substance in the tissue located beneath the skin, rather than into a vein, muscle, nasal cavity, or digestive tract. Epitalon has been administered in this way in numerous studies on longevity and cancer in rodents, as this allows for controlled systemic exposure. However, animal subcutaneous protocols should not be translated into instructions for performing injections in humans.
The subcutaneous route, or s.c., is frequently used in laboratory animal pharmacology because researchers can administer a known amount over a specific period without relying on gastrointestinal absorption.
In a 2003 mouse study, Epitalon was administered subcutaneously at 1 μg per mouse, corresponding to approximately 30–40 μg/kg, for five consecutive days each month. [1]
In the HER-2/neu study, 1 µg was also administered subcutaneously for five consecutive days each month. [2]
A 2006 study on spontaneous tumours in female C3H/He mice used repeated injections of 0.1 μg five times a week for 6.5 months. [7]
These examples show that subcutaneous administration was common in Epitalon research, but the protocols themselves varied considerably.
It is also important not to equate subcutaneous research exposure with intravenous administration. Different injection routes can lead to distinct absorption rates, maximum concentrations, tissue distribution and safety profiles.
No robust human study has established which injection route, if any, provides optimal clinical exposure to Epitalon.
What is the difference between injection and non-injection routes?
Injection and non-injection routes differ in terms of the biological barriers with which Epitalon comes into contact. Injections bypass the gastrointestinal tract, administration via the oral route exposes the peptide to digestion and intestinal absorption, whereas nasal administration involves contact with the nasal mucosa. However, published studies on Epitalon do not provide sufficient pharmacokinetic data in humans to quantitatively compare these differences.
The route of administration affects what happens to the peptide before it reaches its potential target tissues.
Injection
Subcutaneous or intramuscular administration bypasses digestion in the gastrointestinal tract.
This may provide more predictable exposure in animal experiments, but injectable formulations come with other safety considerations, including sterility, particulate contamination, peptide aggregation, impurities and immune reactions.
The FDA currently indicates that compounded Epitalon may be associated with immunogenicity issues for certain routes of administration due to potential aggregation and peptide impurities, and that sufficient safety information has not been identified for the route analysed by the agency.
Oral administration
Oral Epithalon was used in rodent studies.
In old Wistar rats, monthly per os administration altered the activity of several small intestinal enzymes. [5]
This confirms that the oral route was studied experimentally.
However, it does not establish what amount of unchanged Epitalon reaches the human circulation after ingestion.
Short peptides may be broken down by peptidases in the gastrointestinal tract and the brush border, although the exact susceptibility depends on the sequence and formulation. The literature reviewed on Epitalon does not contain robust contemporary pharmacokinetic data in humans determining absolute oral bioavailability.
Intranasal administration
The intranasal route was studied primarily in rats.
In a 2007 study of the neocortex, intranasal administration was chosen as a non-invasive experimental route to facilitate exposure of the central nervous system, and rapid changes in cortical neuronal activity were observed. [4]
An earlier related Russian publication also described similar neuronal responses following intranasal administration of Epitalon. [8]
These results confirm biological activity following intranasal exposure in rats.
They do not establish absolute bioavailability in humans, clinical penetration into the CNS, or superiority over injection or oral administration.
Have the oral, sublingual and nasal forms of Epitalon been studied to the same extent?
No. Oral and intranasal Epitalon have been studied in animal models, but the evidence base is significantly smaller than for subcutaneous administration. However, no significant peer-reviewed literature regarding sublingual administration of Epitalon has been identified. Therefore, these routes should not be presented as equally validated or interchangeable.
The evidence differs significantly depending on the route.
Oral examinations
Oral Epitalon has direct confirmation in published research on rodents.
In a 2002 study on old Wistar rats, Epithalon was administered per os for one month and changes in maltase and alkaline phosphatase activity in the small intestinal epithelium were observed. [5]
Other gastrointestinal studies in rodents have also analysed Epithalon after oral administration.
This means that oral administration is a viable research route, but the evidence pertains to rodent physiology rather than validated human oral absorption or efficacy.
Intranasal studies
The whistleblowing application has a small but clear basis in animal research.
Publications from 2006 and 2007 concerning rat cortical neurones described rapid electrophysiological responses following intranasal administration of Epitalon. [4,8]
In another study on rats, Epitalon was administered intranasally, analysing stress-related changes in the pineal gland and C-Fos expression. The final intranasal exposure was applied two hours before the analysis of the pineal tissue. [9]
These are preclinical studies.
Sublingual testing
No significant peer-reviewed study evaluating specifically the pharmacokinetics, bioavailability, efficacy, or safety of sublingual Epitalon was identified in the analysed literature and targeted PubMed searches.
The lack of such data is significant.
The mere fact of offering a product in sublingual form does not mean that this route has been scientifically characterised.
Statements such as „sublingual Epitalon has X% bioavailability” should therefore be supported by a specific peer-reviewed pharmacokinetic source, rather than assumptions based on other peptides.
How Does the Route of Administration Affect Bioavailability?
The route of administration can significantly affect the bioavailability of Epitalon, but the scale of this effect remains unknown, as published studies do not provide robust comparative pharmacokinetic data in humans measuring absolute bioavailability following subcutaneous, intramuscular, intranasal, oral or sublingual administration.
Bioavailability refers to the proportion and rate at which an administered substance reaches the systemic circulation or, depending on the context, the appropriate biological site in an active form.
For an intravenously administered medicine, systemic bioavailability is standardly considered complete, as the substance goes directly into the circulation.
In the case of the subcutaneous, intramuscular, oral or nasal route, absorption must take place first.
Epitalon has not been characterised to such an extent in humans.
Why an injection might differ
Subcutaneous injection bypasses intestinal digestion, but the substance still needs to be absorbed from the tissue into the circulation.
The speed of this process can depend on the size of the molecule, local blood flow, formulation, concentration and degradation at the injection site.
Rodent studies demonstrate pharmacological effects following subcutaneous administration, but do not determine absolute bioavailability in humans. [1–3,6]
Why oral administration may vary
An orally administered peptide is exposed to the acidic environment of the stomach, digestive enzymes, intestinal peptidases and epithelial transport barriers before reaching the circulation.
Oral studies on rats show that such exposure may be associated with local or physiological changes, but do not indicate what proportion of unchanged AEDG entered the systemic circulation. [5]
Therefore, claims that Epitalon is „fully orally bioavailable” or has a specific percentage of oral absorption are not supported by the analysed evidence.
Why nasal administration can vary
The nasal route allows molecules to come into contact with the highly vascularised nasal mucosa and is being investigated as a method of delivering certain substances into the systemic circulation or the central nervous system.
Epitalon studies on rats showed rapid cortical responses after intranasal administration. [4,8]
However, the description of this pathway by researchers as a way to bypass the blood-brain barrier should be interpreted as experimental justification rather than as proof of quantitatively confirmed direct nose-to-brain transport in humans.
None of the analysed pharmacokinetic studies in humans simultaneously measure the concentration of Epitalon in plasma, cerebrospinal fluid or brain tissue following nasal administration.
What Safety and Sterility Issues Matter in the Laboratory?
Laboratory handling of Epitalon requires consideration of identity, purity, aggregation, impurities, formulation and — where sterile preparations are required — validated aseptic procedures. Peptide or microbiological impurities can distort experimental results and pose safety risks, particularly in the case of materials intended for injection research.
Chemical identity and sterility are distinct quality parameters.
The vial may contain the correct AEDG sequence and at the same time be microbiologically contaminated.
On the other hand, the sterile preparation may contain the wrong peptide, degradation products, aggregates or an incorrect concentration.
For injection testing materials, important quality parameters include:
identity of the active peptide,
cleanliness,
peptide-related impurities,
aggregation,
endotoxin or pyrogen contamination,
microbiological sterility where it is required,
particulate matter pollution,
salt form or counterion,
stability,
and confirmation of the concentration.
The current FDA assessment of compounded Epitalon pays particular attention to aggregation, peptide impurities, and potential immunogenicity, while noting that insufficient safety data have been identified for the route of administration under analysis.
The 2026 FDA warning letter concerning a compounding pharmacy also referenced Epithalon products and documented broader labelling and compounding irregularities, including a lack of information regarding the dosage form and the storage or handling conditions for certain Epithalon products. This is evidence concerning regulatory compliance, not evidence that all Epitalon preparations have such flaws.
For research laboratories, the key principle is simple: the label „Epitalon” alone does not confirm chemical identity, purity, concentration, or sterility.
Analytical methods, such as mass spectrometry and chromatography, can help confirm identity and purity, whereas sterility issues require microbiological methods.
The article does not contain instructions for injection preparation, reconstitution, or aseptic self-administration, as such practical procedures would go beyond the available clinical evidence regarding this experimental peptide.
How Strong is the Evidence for the Various Routes of Administration?
| Application route | Main published evidence | Level of evidence | The most important unresolved question |
|---|---|---|---|
| Subcutaneous | Research on longevity, cancer, the endocrine system and ageing in rodents | Extensive preclinical | Human pharmacokinetics and safety |
| Intramuscular | Older studies on non-human primates | Limited preclinical/primate | Human exposure and comparative efficacy |
| Intranasal | Research on the cerebral cortex and pineal gland in rats | Limited preclinical | Human bioavailability and CNS delivery |
| Oral | Intestinal and gastrointestinal studies in rats | Limited preclinical | Absorption of the unchanged peptide into the circulation in humans |
| Sublingual | There is no significant peer-reviewed literature specific to this route | Essentially uncharacterised | Bioavailability, efficacy and safety |
| Direct cell exposure | Numerous mechanistic studies | In vitro | It is not a clinical route of administration |
The subcutaneous route has the most research history, but this should not be equated with the strongest evidence in humans. Comparative data involving humans remain weak for all routes.
Frequently Asked Questions About Administering Epitalon
Is Epitalon usually administered by injection in research?
Yes. Injections, particularly subcutaneous administration, frequently appear in older animal literature, including longevity and cancer studies. However, Epitalon has also been administered orally and intranasally in preclinical studies. The dominance of injections in animal studies does not mean this is the preferred or approved route of administration in humans. [1–6]
Has nasal Epitalon been studied?
Yes. Intranasal Epitalon has been studied mainly in rats, among other things in experiments evaluating cortical neurone activity and stress-related changes in the pineal gland. Following intranasal exposure, rapid neuronal effects were observed, but these studies do not establish intranasal bioavailability or clinical delivery to the CNS in humans. [4,8,9]
Has oral Epitalon been studied?
Yes, but above all in rodents. Old Wistar rats received Epithalon orally for one month in studies concerning digestive tract enzymes. [5] This confirms the experimental use of the oral route, but does not determine what amount of unchanged peptide is absorbed into the circulation in humans.
Has sublingual Epitalon been studied?
No significant peer-reviewed body of evidence concerning sublingual Epitalon was identified in the literature reviewed. Claims regarding sublingual absorption, percentage bioavailability or the superiority of this route therefore require specific, independent pharmacokinetic data, rather than extrapolation from intranasal or oral studies.
Is injectable Epitalon more bioavailable than oral?
This is biologically plausible, but has not been adequately quantified in humans. Injection bypasses digestion in the gastrointestinal tract, whereas oral Epitalon is subject to digestive and intestinal barriers. However, there is a lack of a robust direct human pharmacokinetic study determining the absolute bioavailability of both routes.
Does intranasal Epitalon cross the blood–brain barrier?
Researchers in rats chose the intranasal route with the intention of facilitating delivery to the CNS and observed rapid changes in cortical neuronal activity. [4] However, these experiments did not quantitatively confirm penetration across the blood-brain barrier in humans, therefore a definitive claim about BBB crossing in humans would go beyond the available evidence.
Has subcutaneous Epitalon proven safety?
No. Some long-term animal studies have not shown obvious toxicity under specific experimental conditions, but controlled safety data for this route in humans are insufficient. The FDA also points out potential issues related to immunogenicity and peptide quality in compounded Epitalon.
Limitations of Evidence Regarding Routes of Administration
The most important limitation is the lack of comparative pharmacokinetics in humans.
Literature shows that Epitalon can be administered to animals via various routes and still produce measurable biological effects. However, it does not state whether the same nominal doses lead to the same systemic exposure.
A second limitation is the strong link between the route of administration and the aim of the study. Subcutaneous studies have typically concerned lifespan or tumours, intranasal studies have analysed neuronal or pineal responses, and oral studies have focused primarily on the physiology of the gastrointestinal tract. Differences in the results cannot therefore be attributed solely to the route of administration.
Thirdly, some older publications describe the nasal route as a way to bypass the blood–brain barrier, but experiments essentially did not directly measure the amount of unchanged Epitalon in brain tissue or cerebrospinal fluid. [4,8] The observed neuronal response confirms biological activity, but does not explain the complete pharmacokinetic pathway.
Fourthly, oral studies in rodents show biological responses following oral administration, but do not confirm systemic absorption of the unchanged peptide in humans.
Fifthly, commercial forms such as oral capsules, sprays, sublingual products and injection vials should not automatically be considered as corresponding to the formulations, purity, salt forms or exposure conditions used in published experiments.
Finally, safety dependent on the route of administration remains poorly defined. The risk profile of an injectably administered peptide includes issues that do not occur in the same way in oral studies, particularly sterility, aggregation and immunogenicity associated with parenteral administration.
Disclaimer
This article is for educational and scientific-informational purposes only and does not constitute medical advice, an injection instruction, a reconstitution instruction, dosage recommendations, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and published evidence regarding subcutaneous, intramuscular, intranasal, and oral administration comes mainly from preclinical studies rather than contemporary controlled human clinical trials. The FDA currently indicates that compounded Epitalon may pose route-dependent immunogenicity risks due to aggregation and peptide-related impurities, and that sufficient safety information has not been identified for the route analysed by the agency.
References
[1] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumour incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714
[2] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provinciali, M., Mancini, R., & Franceschi, C. (2002). Epithalon inhibits tumour growth and expression of HER-2/neu oncogene in breast tumours in transgenic mice characterised by accelerated ageing. Bulletin of Experimental Biology and Medicine, 133(2), 167–170. https://doi.org/10.1023/A:1015555023692
[3] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2007). Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumours in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine, 144(6), 825–830. https://doi.org/10.1007/s10517-007-0441-z
[4] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3
[5] Khavinson, V. K., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Nikitina, A. A. (2002). Effect of Vilon and Epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bulletin of Experimental Biology and Medicine, 134(6), 562–564. https://doi.org/10.1023/A:1022913228900
[6] Kossoy, G., Ben-Hur, H., Popovich, I., Zabezhinski, M., Anisimov, V., Khavinson, V., & Zusman, I. (2003). Epitalon and colon carcinogenesis in rats: Proliferative activity and apoptosis in colon tumors and mucosa. International Journal of Molecular Medicine, 12(4), 473–477. https://pubmed.ncbi.nlm.nih.gov/12964022/
[7] Kossoy, G., Anisimov, V. N., Ben-Hur, H., Kossoy, N., & Zusman, I. (2006). Effect of the synthetic pineal peptide Epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 20(2), 253–257. https://pubmed.ncbi.nlm.nih.gov/16634527/
[8] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nosdrachev, A. D. (2006). Intranasal Epitalon infusion modulates neuronal activity in the rat neocortex. Sechenov Physiological Journal of Russia, 92(8), 949–956. https://pubmed.ncbi.nlm.nih.gov/17217245/
[9] Sibarov, D. A., Nozdrachev, A. D., & Khavinson, V. K. (2002). Epitalon influences pineal secretion in stress-exposed rats in the daytime. Neuro Endocrinology Letters, 23(5–6), 452–454. https://pubmed.ncbi.nlm.nih.gov/12500171/